ABT-263
| Title | Journal |
|---|---|
| Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. | Toxicology in vitro : an international journal published in association with BIBRA 20180201 |
| Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling. | Chemico-biological interactions 20160425 |
| Antioncogenic and Oncogenic Properties of Nrf2 in Arsenic-induced Carcinogenesis. | The Journal of biological chemistry 20151106 |
| Nrf2/p62 signaling in apoptosis resistance and its role in cadmium-induced carcinogenesis. | The Journal of biological chemistry 20141010 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. | Biochemical pharmacology 20130401 |
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. | Nature medicine 20130201 |
| Bax and Bcl-xL exert their regulation on different sites of the ceramide channel. | The Biochemical journal 20120701 |
| Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. | Cell death & disease 20120701 |
| In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution. | Cancer research 20120615 |
| Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. | Blood 20120614 |
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120601 |
| Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. | Molecular cancer therapeutics 20120401 |
| ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. | Cancer chemotherapy and pharmacology 20120301 |
| WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. | Laboratory investigation; a journal of technical methods and pathology 20120301 |
| 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120301 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ. | PloS one 20120101 |
| Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. | The Journal of pharmacology and experimental therapeutics 20111201 |
| The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. | Molecular cancer therapeutics 20111201 |
| Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. | Biochemical pharmacology 20111101 |
| Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis. | Cell death & disease 20111101 |
| Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. | Pathology 20111001 |
| Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. | Blood 20110811 |
| Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. | Experimental hematology 20110801 |
| Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. | Cancer research 20110701 |
| BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. | Blood 20110630 |
| Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110615 |
| The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. | Biochemical and biophysical research communications 20110506 |
| Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity. | Journal of medicinal chemistry 20110324 |
| Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110315 |
| ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. | Oncology reports 20110301 |
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110301 |
| Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. | PloS one 20110101 |
| Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. | PloS one 20110101 |
| Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. | The Lancet. Oncology 20101201 |
| A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). | Molecular cancer therapeutics 20101101 |
| Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737. | Cancer biology & therapy 20101101 |
| Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. | Journal of medicinal chemistry 20101014 |
| The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. | Cancer chemotherapy and pharmacology 20101001 |
| Drugs targeting Bcl-2 family members as an emerging strategy in cancer. | Expert reviews in molecular medicine 20100908 |
| Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100815 |
| Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. | Molecular cancer therapeutics 20100301 |
| Aileron staples peptides. | Chemistry & biology 20090925 |
| Update on developmental therapeutics for acute lymphoblastic leukemia. | Current hematologic malignancy reports 20090701 |
| Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. | Cell death and differentiation 20090301 |
| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. | Journal of cellular physiology 20090101 |
| Mimicking the BH3 domain to kill cancer cells. | Oncogene 20081201 |
| Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. | Journal of medicinal chemistry 20081113 |
| ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. | Molecular cancer therapeutics 20081001 |
| Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. | Pediatric blood & cancer 20080601 |
| Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. | Cancer research 20080501 |
| A matter of life and death. | Cancer cell 20020201 |
| An informatics approach identifying markers of chemosensitivity in human cancer cell lines. | Cancer research 20001101 |